Research Reports | Market Assessment
December 2017

Chronic Myeloid Leukemia | Current Treatment | Physician Insights | US | 2017

Chronic myeloid leukemia is a slow progressive tumor, characterized by different phases of disease (chronic, accelerated, and blast). Treatment of chronic myeloid leukemia is dominated by oral BCR-ABL tyrosine kinase inhibitors. Treatment options for newly diagnosed chronic phase disease are dominated by TKIs, including first-to-market Gleevec (Novartis), Sprycel (Bristol-Myers Squibb), and Tasigna (Novartis); treatment options for patients who are resistant or intolerant to prior therapy (and in patients with accelerated and/or blast phase disease) include Bosulif (Pfizer), Iclusig (Ariad), and Synribo (Teva).

Questions Answered:

  • What percentage of drug-treated, newly diagnosed, chronic phase chronic myeloid leukemia patients are prescribed BCR-ABL tyrosine kinase inhibitors as first-line and second-line treatment by surveyed physicians?
  • What are the key drivers and obstacles determining current prescribing patterns in the chronic myeloid leukemia treatment armamentarium?
  • How the entry of generic Gleveec has affected the treatment preference of hematologists?
  • What are surveyed physicians’ perceptions of the intended duration of tyrosine kinase inhibitor treatment for chronic myeloid leukemia versus their actual clinical practice? To what extent are their patients compliant?

Product Description:

Current Treatment: Provides physician insights on prescribing behavior, treatment paths, and the factors and perceptions driving brand usage so you can understand each brand’s performance and improve or defend your competitive position.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports